Carmat SA
PAR:ALCAR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.066
7.6805
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Carmat SA
Carmat SA
Cost of Revenue
Carmat SA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Carmat SA
PAR:ALCAR
|
Cost of Revenue
-€35.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-8%
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Cost of Revenue
-€36m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Biomerieux SA
PAR:BIM
|
Cost of Revenue
-€1.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Biosynex SA
PAR:ALBIO
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Visiomed Group SA
PAR:ALVMG
|
Cost of Revenue
-€789k
|
CAGR 3-Years
64%
|
CAGR 5-Years
30%
|
CAGR 10-Years
17%
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Cost of Revenue
-€21.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Carmat SA
Glance View
Carmat SA engages in the developing of implantable orthotropic and biocompatible artificial heart. The company is headquartered in Velizy-Villacoublay, Ile-De-France and currently employs 160 full-time employees. The company went IPO on 2010-07-07. The firm is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The firm formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels and Blood Institute, Laboratoire de Recherche Biochirurgicale and others. As of December 31, 2011, a company MATRA DEFENSE held a 30.57% stake in the Company’s shareholdings.
See Also
What is Carmat SA's Cost of Revenue?
Cost of Revenue
-35.1m
EUR
Based on the financial report for Jun 30, 2024, Carmat SA's Cost of Revenue amounts to -35.1m EUR.
What is Carmat SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-8%
Over the last year, the Cost of Revenue growth was -18%. The average annual Cost of Revenue growth rates for Carmat SA have been -4% over the past three years , -1% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet
